ADmit Therapeutics has announced the publication of a blood biomarker in the journal iScience. The study details the fundamental research that led to the development of the Test MAP-AD®, a prognostic...
Read more
The MAP-AD® Test is a qualitative in vitro diagnostic (IVD) blood test for the prognosis of the progression from Mild Cognitive Impairment to AD dementia in adult patients between 55 and 85 years old...
Read more
The Lancet Neurology publishes the new criteria, the result of a global expert consensus led by Dr Xavier Montalban.
Read more
El test sanguíneo MAP-AD® de la compañía ADmit Therapeutics, spin-off del IDIBELL, con el Hospital de Bellvitge como centro coordinador clínico, logra un hito regulatorio con el marcado CE y abre...
Read more
Oryzon Genomics is proud to announce its participation as a sponsor of the first-ever Phelan-McDermid syndrome (PMS) burden of illness study. The study is led by CureShank, a research advocacy organiz...
Read more
Estos hitos, más allá de marcar un notable avance terapéutico, representan la urgencia de mejorar el diagnóstico precoz, de definir claramente los criterios de acceso, de vigilancia de efectos adv...
Read more
Full Professor of Microbiology Ignacio López-Goñi, director of the UCC+I at the University of Navarra, explains in Microbiota and mental health how the link between gut bacteria and the brain could ...
Read more
La aprobación de nuevos medicamentos con anticuerpos para la enfermedad de Alzheimer –lecanemab y donanemab– y de pruebas diagnósticas en sangre marcan el inicio de una nueva era en el diagnóst...
Read more
Este biomarcador permite detectar la presencia de depósitos de beta amiloide, patología clave en el desarrollo de la enfermedad, en personas sin deterioro cognitivo
Read more
The studies established the lead asset SYT-510 to be well tolerated in healthy volunteers at all doses with a good safety profile
Read more
Se trata de una enfermedad minoritaria de origen genético caracterizada por dificultades progresivas en la coordinación motora, infecciones recurrentes y predisposición al cáncer.
Read more
FreeOx has developed the first cerebroprotective therapy designed to preserve the brain during acute ischemic stroke. It is the key piece in stroke treatment, as it focuses on microcirculation and sol...
Read more
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
Telum Therapeutics, a biotechnology company leveraging proprietary met...
